ArticleEpidemics2022
Calibrating COVID-19 community transmission risk levels to reflect infection prevalence.
Article in Epidemics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Interpreting epidemiological surveillance data: a modelling study based on Pune city.Scientific reports · 2025Article
- Infection prevention behaviors and perceptions of nurses in a medical intensive care unit.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Evaluation of the US Definitions for Coronavirus Disease 2019 Community Risk Levels.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many organizations, including the US Centers for Disease Control and Prevention, have developed risk indexes to help determine community transmission levels for the ongoing COVID-19 pandemic. These risk indexes are largely based on newly reported cases and percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests, which are well-established as biased estimates of COVID-19 transmission. However, transmission risk indexes should accurately and precisely communicate community risks to decision-makers and the public. Therefore, transmission risk indexes would ideally quantify actual, and not just reported, levels of disease prevalence or incidence. Here, we develop a robust data-driven framework for determining and communicating community transmission risk levels using reported cases and test positivity. We use this framework to evaluate the previous CDC community risk level metrics that were proposed as guidelines for determining COVID-19 transmission risk at community level in the US. Using two recently developed data-driven models for COVID-19 transmission in the US to compute community-level prevalence, we show that there is substantial overlap of prevalence between the different community risk levels from the previous CDC guidelines. Using our proposed framework, we redefined the risk levels and their threshold values. We show that these threshold values would have substantially reduced the overlaps of underlying community prevalence between counties/states in different community risk levels between 3/19/2020-9/9/2021. Our study demonstrates how the previous CDC community risk level indexes could have been calibrated to infection prevalence to improve their power to accurately determine levels of COVID-19 transmission in local communities across the US. This method can be used to inform the design of future COVID-19 transmission risk indexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.